Cost-Effectiveness of Ketamine Therapy: Health Economic Evidence

Introduction: The Economic Dimensions of Ketamine Therapy

The economic evaluation of ketamine therapy has become an essential component of the clinical and policy discourse as this intervention transitions from research novelty to mainstream treatment option. Cost-effectiveness analysis of ketamine therapy integrates direct treatment costs, comparator treatment costs, clinical outcomes, quality of life gains, and broader societal economic impacts to determine whether ketamine represents good value within healthcare resource allocation frameworks (Ross and Soeteman, 2020). This analysis is particularly pertinent given the substantial economic burden of treatment-resistant depression -- estimated at $40,000 to $90,000 per patient annually in the United States when accounting for direct medical costs, lost productivity, and caregiver burden (Mrazek et al., 2014).

The economic landscape of ketamine therapy is complicated by the coexistence of two distinct treatment models: FDA-approved intranasal esketamine (Spravato), priced at the premium level typical of branded specialty pharmaceuticals, and off-label generic racemic intravenous ketamine, available at a fraction of the cost but without the regulatory validation and standardized delivery framework of the branded product. Understanding the relative cost-effectiveness of these approaches -- and their comparative value against existing TRD interventions -- is essential for informed clinical decision-making, insurance coverage policy, and equitable resource allocation.

Direct Treatment Costs

Intravenous Racemic Ketamine

The direct costs of IV racemic ketamine therapy include:

• Drug acquisition: Generic racemic ketamine costs approximately $5-15 per treatment dose (0.5 mg/kg for a typical adult, drawn from a 500 mg/10 mL vial)
• Clinic overhead: Infusion chair or bed, IV supplies, monitoring equipment amortization, and facility costs -- estimated at $50-150 per session
• Nursing support: Dedicated nursing time for IV access, infusion monitoring, and post-infusion observation (typically 2.5-3 hours) -- estimated at $75-150 per session
• Physician oversight: Prescriber time for assessment, order entry, and session oversight -- estimated at $50-200 per session depending on provider model
• Total per-session cost: $200-500 at cost-based models; $400-1,000 at commercial ketamine clinic pricing (reflecting margin)

For a standard induction course (six infusions over 2-3 weeks) followed by maintenance infusions (biweekly to monthly), first-year costs range from approximately $3,000-8,000 at cost-based models and $5,000-15,000 at commercial clinics.

Intranasal Esketamine (Spravato)

The costs of esketamine therapy include:

• Drug acquisition: Wholesale acquisition cost of approximately $590 for the 56 mg dose and $885 for the 84 mg dose per session
• REMS-mandated facility costs: Certified treatment center overhead, monitoring equipment, dedicated observation space
• Staff time: 2-hour supervised observation period post-administration, with vital signs monitoring
• Total per-session cost: Approximately $800-1,200 including drug and facility costs

Following the approved dosing schedule (twice-weekly for month one, weekly for month two, weekly or every-two-weeks for months three and beyond), first-year esketamine costs may reach $25,000-45,000 at list price, though insurance coverage, copay assistance programs, and rebates substantially modify out-of-pocket costs.

Cost Comparison

The per-session and annual cost differential between generic IV ketamine and branded esketamine is substantial -- approximately 3-5 fold on a per-session basis and potentially greater on an annual basis depending on maintenance frequency. This cost disparity has generated significant debate about the value proposition of the branded product and whether the regulatory framework, standardized delivery, and insurance coverage pathway of esketamine justify the premium pricing.

Comparator Treatment Costs

Conventional Pharmacotherapy

The annual costs of conventional TRD pharmacotherapy vary widely:

• Generic SSRIs/SNRIs: $50-500 per year for medication alone, plus monitoring visits
• Lithium augmentation: $200-600 per year for medication, plus laboratory monitoring costs (lithium levels, thyroid, renal function) adding $300-600 annually
• Atypical antipsychotic augmentation: $1,000-6,000 per year for branded agents (aripiprazole, quetiapine extended-release), with generic options at lower cost. Metabolic monitoring adds $300-500 annually
• Total pharmacotherapy costs in TRD: Typically $2,000-8,000 annually, depending on the complexity of the regimen

Electroconvulsive Therapy

ECT, the traditional intervention for severe TRD, carries substantial per-session costs due to the requirement for general anesthesia:

• Per-session cost: $800-2,500 (including anesthesia, facility, physician, and recovery room costs)
• Acute course (6-12 sessions): $5,000-30,000
• Maintenance ECT (monthly): $10,000-30,000 per year

ECT costs are generally covered by insurance but represent a significant healthcare expenditure. The requirement for general anesthesia, an anesthesiologist, and operating room or procedural suite access drives the cost substantially above ketamine infusion.

Repetitive Transcranial Magnetic Stimulation

rTMS involves:

• Per-session cost: $200-400 (technician-administered, no anesthesia)
• Standard course (30-36 sessions over 6 weeks): $6,000-12,000
• Annual maintenance: Variable; $3,000-8,000 if booster courses are needed

Cost-Effectiveness Analyses

Published Economic Evaluations

Ross and Soeteman (2020), published in JAMA Network Open, conducted the first comprehensive cost-effectiveness analysis comparing IV ketamine and intranasal esketamine with treatment-as-usual (TAU) for TRD. Using a Markov model with a 5-year time horizon, the analysis found:

• IV ketamine versus TAU: Incremental cost-effectiveness ratio (ICER) of approximately $36,000-56,000 per quality-adjusted life year (QALY), depending on assumptions about maintenance frequency and response durability. This ICER falls below the commonly cited willingness-to-pay threshold of $50,000-100,000 per QALY, suggesting favorable cost-effectiveness.
• Esketamine versus TAU: Higher ICER of approximately $100,000-200,000 per QALY, driven primarily by the branded drug cost. At list price, esketamine approaches or exceeds conventional willingness-to-pay thresholds, though sensitivity analyses demonstrate that cost-effectiveness improves substantially if drug costs decline.
• IV ketamine versus esketamine: IV ketamine dominated esketamine in the base case (lower cost with equivalent or superior efficacy), though this comparison is limited by the absence of head-to-head clinical trials.

Ho and colleagues (2022) published a budget impact analysis examining the financial implications of incorporating esketamine into a health plan formulary, estimating incremental per-member-per-month costs of approximately $0.02-0.05 -- a modest budget impact reflecting the small eligible population. However, this analysis did not account for potential cost offsets from reduced hospitalizations, ED visits, and disability.

Key Cost-Effectiveness Drivers

Sensitivity analyses consistently identify several factors as primary drivers of ketamine cost-effectiveness:

• Response durability: Longer maintenance of response between treatments substantially improves cost-effectiveness by reducing the total number of sessions required
• Drug acquisition cost: The branded-generic cost differential is the primary driver of the esketamine-versus-IV ketamine comparison
• Comparator treatment costs avoided: Cost savings from reduced hospitalizations, ED visits, and pharmacotherapy trials in patients who respond to ketamine improve the overall cost-effectiveness calculation
• Suicide prevention: Inclusion of suicide-related costs (hospitalization, lost productivity, mortality) substantially favors ketamine given its demonstrated anti-suicidal effects, though modeling these outcomes requires assumptions about ketamine's impact on actual suicide rates rather than just ideation scores

Indirect and Societal Costs

Productivity and Disability

Treatment-resistant depression is associated with profound functional impairment and workforce productivity loss. The indirect costs -- including absenteeism, presenteeism (reduced on-the-job productivity), and disability payments -- often exceed direct medical costs. Greenberg and colleagues (2015) estimated that workplace costs account for approximately 50% of the total economic burden of depression, with TRD patients incurring approximately 2-3 times the workplace costs of treatment-responsive depression, published in Journal of Clinical Psychiatry.

If ketamine therapy reduces functional impairment and enables workforce reengagement -- as suggested by clinical trial data showing improvement in Sheehan Disability Scale scores -- the societal cost-effectiveness of the intervention may be substantially more favorable than analyses limited to direct medical costs suggest. Incorporating productivity gains into cost-effectiveness models typically reduces the ICER by 30-50%.

Hospitalization Avoidance

Each psychiatric hospitalization for depression or suicidality costs approximately $7,000-15,000 in the United States. If maintenance ketamine therapy prevents even one to two hospitalizations per year, the cost offset may approach or exceed the direct cost of treatment. Retrospective studies suggest that patients receiving maintenance ketamine demonstrate reduced hospitalization rates compared with historical baselines, though prospective controlled data are lacking (Cusin et al., 2017).

Caregiver Burden

The economic impact on caregivers of TRD patients -- including reduced work hours, career limitations, and psychological burden -- represents an additional societal cost that is rarely captured in formal economic evaluations. Rapid and sustained improvement in depression severity with ketamine may relieve caregiver burden and produce cascading economic benefits for family units.

Payer Perspectives and Coverage Policy

Insurance Coverage Landscape

The insurance coverage landscape for ketamine therapy varies significantly:

• Esketamine (Spravato): Covered by most commercial insurance plans and Medicare Part D for the approved indication (TRD), subject to prior authorization requirements (typically documentation of two failed antidepressant trials). Patient copays vary widely ($0-300 per session depending on plan design and copay assistance).
• IV racemic ketamine: Insurance coverage is inconsistent and often denied as an off-label use. Some plans provide coverage under medical benefit for in-office infusion, while others categorically exclude off-label ketamine. Most patients pay out-of-pocket at commercial ketamine clinic prices.

This coverage disparity creates an access paradox: the more cost-effective treatment (generic IV ketamine) is less likely to be covered by insurance, while the less cost-effective treatment (branded esketamine) has a defined coverage pathway. This situation drives some patients toward esketamine despite the higher system cost, while others unable to afford either option go without treatment.

Value-Based Contracting

Emerging payment models, including outcomes-based contracts and value-based pricing arrangements, could better align ketamine therapy costs with demonstrated clinical value. Under such models, payment could be contingent on achieving predefined clinical outcomes (depression response or remission), with rebates or price adjustments if outcomes are not met. These models are being explored for other high-cost specialty medications and could be applied to esketamine or clinic-based IV ketamine programs.

Access and Equity Considerations

Geographic Disparities

Ketamine therapy access is concentrated in urban and suburban areas with specialized clinics. Rural populations face substantial barriers including distance to treatment centers, limited provider availability, and higher per-treatment costs due to lower patient volumes. Telemedicine-supported home-based oral ketamine protocols may partially address geographic disparities but introduce their own safety and monitoring challenges.

Socioeconomic Disparities

The out-of-pocket cost burden of ketamine therapy disproportionately affects lower-income patients, who may be least able to afford treatment despite carrying the greatest depression burden. Sliding-scale fee structures, patient assistance programs, and policy efforts to standardize insurance coverage could mitigate but not eliminate these disparities.

Future Economic Research Needs

Key research priorities for the health economics of ketamine therapy include prospective cost-effectiveness trials with long-term follow-up, real-world effectiveness studies comparing IV ketamine and esketamine with comprehensive economic data collection, budget impact analyses incorporating indirect costs and suicide prevention benefits, and equity-focused analyses examining differential access and outcomes across socioeconomic and demographic subgroups.

Conclusion

The cost-effectiveness of ketamine therapy for treatment-resistant depression appears favorable when evaluated against the substantial clinical and economic burden of inadequately treated TRD. Generic IV racemic ketamine demonstrates a more favorable cost-effectiveness profile than branded esketamine, primarily due to the drug acquisition cost differential, though the access and coverage advantages of the branded product complicate direct comparison. The incorporation of indirect costs -- particularly productivity gains, hospitalization avoidance, and suicide prevention -- substantially strengthens the economic case for ketamine therapy. As the evidence base matures and payment models evolve, the economic evaluation of ketamine will increasingly inform clinical practice guidelines, insurance coverage policy, and resource allocation decisions that determine which patients can access this transformative but costly intervention.

References

• PubMed: Cost-Effectiveness of Esketamine vs. IV Ketamine for Treatment-Resistant Depression — Markov model comparing costs and QALYs of esketamine nasal spray versus intravenous ketamine under healthcare sector and patient perspectives
• CMS: Centers for Medicare & Medicaid Services — Federal agency overseeing Medicare and Medicaid coverage policy relevant to ketamine and esketamine reimbursement
• NIMH: Depression Overview — National Institute of Mental Health clinical information on depressive disorders including treatment-resistant depression burden
• MedlinePlus: Esketamine Nasal Spray Drug Information — National Library of Medicine prescribing information for Spravato including approved indications and coverage context